Bromantane
A small placebo trial found faster and larger improvement in asthenic symptoms with oral Ladasten, and a 728-patient uncontrolled report also described short-term response. Bromantane is a Russian prescription drug for asthenic conditions. A 10-person healthy-volunteer experiment found no improvement in core task performance.
Adamantane-derived small-molecule antiasthenic drug
- Small molecule, not a peptide
- Marketed in Russia as Ladasten
- Listed by WADA as an in-competition stimulant
What substance and product do the studies concern?
Bromantane, also indexed as bromantan or adamantylbromophenylamine, is an adamantane-derived small molecule. The clinical reports concern oral Ladasten tablets, so their findings do not authenticate a bulk chemical or online nootropic product.
The current Russian reference entry describes 50 mg and 100 mg prescription tablets containing adamantylbromophenylamine. Bromantane is not a peptide and has no amino-acid sequence.
Ladasten label reproduction · indication, PK, safety
Current drug-reference and label reproduction
Vidal Russia, updated December 6, 2023; registration metadata dated May 16, 2024
The entry lists prescription 50 mg and 100 mg tablets, Russian registration ЛП-№(005486)-(РГ-RU), asthenic-state and neurasthenia indications, label pharmacokinetic values, contraindications, adverse reactions, and two interaction statements.
- Reported label values: Cmax 363.3 ng/mL, Tmax 2 to 4 hours, half-life 11.21 hours.
- No underlying pharmacokinetic study or variability data are cited.
- Participants / model
- Adults covered by the reproduced Russian Ladasten instruction
- Treatment
- Oral adamantylbromophenylamine tablets
- Record context
- Product instruction
- Study design
- Russian-language drug-reference reproduction of an approved instruction
This secondary reproduction is neither the official GRLS interface nor a primary pharmacokinetic report.
Read the original sourceWhat is Bromantane's current regulatory status?
A Russian drug-reference reproduction lists Ladasten under replacement registration ЛП-№(005486)-(РГ-RU), dated May 16, 2024 with an indefinite term. The older GRLS-derived record is inactive and links to that replacement. This is secondary registration metadata rather than an official GRLS record.
The reproduced Russian indication is treatment of asthenic states of various origins, including after somatic illness or infection, and neurasthenia. It is not a general approval for cognition, motivation, sport, or fatigue in an otherwise healthy person.
FDA Drugs@FDA records contained no exact-name match for bromantane, bromantan, or adamantylbromophenylamine.
Ladasten label reproduction · indication, PK, safety
Current drug-reference and label reproduction
Vidal Russia, updated December 6, 2023; registration metadata dated May 16, 2024
The entry lists prescription 50 mg and 100 mg tablets, Russian registration ЛП-№(005486)-(РГ-RU), asthenic-state and neurasthenia indications, label pharmacokinetic values, contraindications, adverse reactions, and two interaction statements.
- Reported label values: Cmax 363.3 ng/mL, Tmax 2 to 4 hours, half-life 11.21 hours.
- No underlying pharmacokinetic study or variability data are cited.
- Participants / model
- Adults covered by the reproduced Russian Ladasten instruction
- Treatment
- Oral adamantylbromophenylamine tablets
- Record context
- Product instruction
- Study design
- Russian-language drug-reference reproduction of an approved instruction
This secondary reproduction is neither the official GRLS interface nor a primary pharmacokinetic report.
Read the original sourceRussian register metadata · replacement link
Secondary regulatory record
Pharm-Portal GRLS reference.
The older ЛСР-010257/08 record is marked inactive and links to replacement registration ЛП-№(005486)-(РГ-RU).
- Participants / model
- Russian Ladasten registration records
- Treatment
- Adamantylbromophenylamine
- Follow-up
- Older record registered December 19, 2008
- Study design
- Third-party reproduction of state-register metadata
The cited source is a third-party reproduction rather than an official GRLS record.
Read the original sourceFDA records · no exact-name match
Regulatory database record set
openFDA Drugs@FDA records
Drugs@FDA records contained no match under bromantane, bromantan, or adamantylbromophenylamine.
- Participants / model
- FDA drug-application records exposed through openFDA
- Treatment
- Bromantane name and aliases
- Study design
- Exact-name U.S. approval coverage
How strong is the controlled evidence in neurasthenia?
The 2009 Russian trial found faster and larger improvement in asthenic symptoms with Ladasten than placebo. It randomized 30 patients with situational asthenic symptoms or neurasthenia, 15 per group, and was described as single-blind. Treatment lasted 28 days, followed by one week on placebo.
Ladasten was started at 100 mg a day in two doses and could be adjusted to 50 to 150 mg a day. The report describes faster and larger improvement in asthenic symptoms with Ladasten, but all 15 active recipients completed while only 7 of 15 placebo recipients did. Eight placebo patients stopped on days 14 to 19 for absent or minimal benefit or worsening, which makes the between-group estimate fragile.
The authors reported no withdrawal syndrome during the one-week placebo phase. That brief observation in a tiny trial does not establish absence of dependence or withdrawal after longer use.
2009 Russian placebo trial · n=30, high placebo attrition
Randomized single-blind placebo-controlled trial
Neznamov et al., Zhurnal Nevrologii i Psikhiatrii, 2009
Asthenic symptoms improved faster and more strongly with Ladasten, but 8 of 15 placebo recipients stopped early for poor effect or worsening while all 15 active recipients completed.
- No withdrawal syndrome was reported during one week after the 28-day treatment phase.
- The differential attrition makes the apparent treatment effect hard to estimate reliably.
- Participants / model
- 30 patients with situational asthenic symptoms or neurasthenia, 15 per group
- Treatment
- Ladasten initially 100 mg/day in two doses, adjustable to 50 to 150 mg/day, versus matched placebo
- Follow-up
- 28 days plus a one-week placebo withdrawal phase
- Study design
- Russian-language full report of a randomized, single-blind, placebo-controlled trial
Randomization method and allocation concealment were not described in the report, and placebo attrition was severe.
Read the original sourceWhat did the large Russian report find?
The 2011 report described high investigator-rated response and low short-term adverse-event rates among 728 patients treated for 28 days at 28 Russian centers. The indexed abstract does not identify a randomized control group, so time, expectation, and concurrent care could contribute to the results.
The authors reported response rates of 76.0% by CGI-S and 90.8% by CGI-I, adverse events in 3.0%, discontinuation for adverse events in 0.8%, and no serious adverse events. Those are uncontrolled, investigator-rated outcomes from a 28-day product study, not proof of benefit or long-term safety.
2011 multicenter report · uncontrolled n=728
Multicenter observational treatment report
Avedisova et al., Zhurnal Nevrologii i Psikhiatrii, 2011
Among 728 analyzed patients, the report gives CGI-S and CGI-I response rates of 76.0% and 90.8%, adverse events in 3.0%, discontinuation in 0.8%, and no serious adverse events during 28 days.
- Participants / model
- 728 analyzed patients with asthenic disorders and psychoautonomic syndrome across 28 Russian centers
- Treatment
- Oral Ladasten 50 to 100 mg daily
- Follow-up
- 28 days, with a reported one-month follow-up
- Study design
- Russian multicenter report; no controlled allocation stated in the indexed abstract
The abstract describes no controlled allocation.
Read the original sourceDid Bromantane improve cognition or performance in healthy volunteers?
The healthy-person evidence is a Russian report of 10 untired men after one oral dose compared with placebo. The abstract says bromantane did not change subjective state or the main components of operator performance.
It reported EEG patterns interpreted as increased vigilance and less tremor, then speculated about reserve performance under fatigue or extreme conditions. The experiment did not measure durable attention, memory, motivation, or real-world performance.
2000 Russian healthy-volunteer study · n=10 acute
Small acute placebo comparison
Viatleva et al., Voenno-Meditsinskii Zhurnal, 2000
In 10 healthy untired men after one oral dose, the abstract reports no change in subjective state or principal operator-performance components, with EEG vigilance and tremor differences interpreted as favorable.
- Participants / model
- 10 healthy, untired male volunteers
- Treatment
- Single oral bromantane exposure versus placebo
- Follow-up
- Acute laboratory assessment
- Study design
- Russian-language comparative report with an English abstract
The English abstract omits the dose. The study did not measure durable cognitive or functional benefit.
Read the original sourceWhat does the label report about half-life and safety?
The current Russian label reproduction states a 2-to-4-hour time to peak, a peak concentration of 363.3 ng/mL, and an 11.21-hour half-life. It provides no study citation, sample size, dose, concentration-time table, or variability, so the value rests on the label rather than a primary human pharmacokinetic report.
The reproduced label lists excessive activation, difficulty falling asleep, and allergic reactions. It lists pregnancy, breastfeeding, age under 18, and individual intolerance as contraindications.
Its interaction section says Ladasten reduces the hypnotic effect of sodium thiopental and does not weaken benzodiazepine anxiolysis. The label lists no other interaction data, and the cited human reports do not establish safety with months or years of exposure.
Ladasten label reproduction · indication, PK, safety
Current drug-reference and label reproduction
Vidal Russia, updated December 6, 2023; registration metadata dated May 16, 2024
The entry lists prescription 50 mg and 100 mg tablets, Russian registration ЛП-№(005486)-(РГ-RU), asthenic-state and neurasthenia indications, label pharmacokinetic values, contraindications, adverse reactions, and two interaction statements.
- Reported label values: Cmax 363.3 ng/mL, Tmax 2 to 4 hours, half-life 11.21 hours.
- No underlying pharmacokinetic study or variability data are cited.
- Participants / model
- Adults covered by the reproduced Russian Ladasten instruction
- Treatment
- Oral adamantylbromophenylamine tablets
- Record context
- Product instruction
- Study design
- Russian-language drug-reference reproduction of an approved instruction
This secondary reproduction is neither the official GRLS interface nor a primary pharmacokinetic report.
Read the original source2011 multicenter report · uncontrolled n=728
Multicenter observational treatment report
Avedisova et al., Zhurnal Nevrologii i Psikhiatrii, 2011
Among 728 analyzed patients, the report gives CGI-S and CGI-I response rates of 76.0% and 90.8%, adverse events in 3.0%, discontinuation in 0.8%, and no serious adverse events during 28 days.
- Participants / model
- 728 analyzed patients with asthenic disorders and psychoautonomic syndrome across 28 Russian centers
- Treatment
- Oral Ladasten 50 to 100 mg daily
- Follow-up
- 28 days, with a reported one-month follow-up
- Study design
- Russian multicenter report; no controlled allocation stated in the indexed abstract
The abstract describes no controlled allocation.
Read the original sourceCan an athlete use Bromantane under WADA rules?
Bromantan is named in section S6.A of WADA's 2026 Prohibited List as a non-specified stimulant prohibited in competition. A Russian prescription or medical indication does not by itself remove that anti-doping rule.
WADA 2026 · Bromantan prohibited in competition
Official anti-doping standard
World Anti-Doping Agency, effective January 1, 2026
Bromantan appears in S6.A among non-specified stimulants prohibited in competition.
- Participants / model
- Athletes subject to the World Anti-Doping Code
- Treatment
- Bromantan exposure
- Follow-up
- 2026 Prohibited List
- Study design
- Official regulatory standard
Therapeutic-use exemption rules are separate and depend on the applicable anti-doping process.
Read the original sourceDoes Bromantane work by increasing dopamine synthesis?
That mechanism is supported mainly by preclinical work. A Russian rat study found that 50 mg/kg Ladasten changed tyrosine hydroxylase and DOPA decarboxylase gene expression and was associated with higher L-DOPA and dopamine in parts of the brain.
The experiment involved rat striatum and hypothalamus, not people taking the marketed dose. Human symptom improvement does not prove that this pathway mediates the clinical result.
Rat mechanism study · dopamine-synthesis enzymes
Preclinical mechanism study
Vakhitova et al., Eksperimentalnaia i Klinicheskaia Farmakologiia, 2004
After 50 mg/kg Ladasten in rats, changes in tyrosine hydroxylase and DOPA decarboxylase expression correlated with L-DOPA and dopamine accumulation in striatum and hypothalamus.
- Participants / model
- Laboratory rats
- Treatment
- Ladasten 50 mg/kg
- Follow-up
- Time-course over the first hours after exposure
- Study design
- Russian preclinical gene-expression and neurochemistry experiment with an English abstract
- Funding
- Non-U.S. government research support indexed by PubMed
No human experiment in this source tested the mechanism, effect size, or dose relationship.
Read the original sourceStudies and sources
Ladasten label reproduction · indication, PK, safety
Current drug-reference and label reproduction
Vidal Russia, updated December 6, 2023; registration metadata dated May 16, 2024
The entry lists prescription 50 mg and 100 mg tablets, Russian registration ЛП-№(005486)-(РГ-RU), asthenic-state and neurasthenia indications, label pharmacokinetic values, contraindications, adverse reactions, and two interaction statements.
- Reported label values: Cmax 363.3 ng/mL, Tmax 2 to 4 hours, half-life 11.21 hours.
- No underlying pharmacokinetic study or variability data are cited.
- Participants / model
- Adults covered by the reproduced Russian Ladasten instruction
- Treatment
- Oral adamantylbromophenylamine tablets
- Record context
- Product instruction
- Study design
- Russian-language drug-reference reproduction of an approved instruction
This secondary reproduction is neither the official GRLS interface nor a primary pharmacokinetic report.
Read the original sourceRussian register metadata · replacement link
Secondary regulatory record
Pharm-Portal GRLS reference.
The older ЛСР-010257/08 record is marked inactive and links to replacement registration ЛП-№(005486)-(РГ-RU).
- Participants / model
- Russian Ladasten registration records
- Treatment
- Adamantylbromophenylamine
- Follow-up
- Older record registered December 19, 2008
- Study design
- Third-party reproduction of state-register metadata
The cited source is a third-party reproduction rather than an official GRLS record.
Read the original sourceFDA records · no exact-name match
Regulatory database record set
openFDA Drugs@FDA records
Drugs@FDA records contained no match under bromantane, bromantan, or adamantylbromophenylamine.
- Participants / model
- FDA drug-application records exposed through openFDA
- Treatment
- Bromantane name and aliases
- Study design
- Exact-name U.S. approval coverage
2009 Russian placebo trial · n=30, high placebo attrition
Randomized single-blind placebo-controlled trial
Neznamov et al., Zhurnal Nevrologii i Psikhiatrii, 2009
Asthenic symptoms improved faster and more strongly with Ladasten, but 8 of 15 placebo recipients stopped early for poor effect or worsening while all 15 active recipients completed.
- No withdrawal syndrome was reported during one week after the 28-day treatment phase.
- The differential attrition makes the apparent treatment effect hard to estimate reliably.
- Participants / model
- 30 patients with situational asthenic symptoms or neurasthenia, 15 per group
- Treatment
- Ladasten initially 100 mg/day in two doses, adjustable to 50 to 150 mg/day, versus matched placebo
- Follow-up
- 28 days plus a one-week placebo withdrawal phase
- Study design
- Russian-language full report of a randomized, single-blind, placebo-controlled trial
Randomization method and allocation concealment were not described in the report, and placebo attrition was severe.
Read the original source2011 multicenter report · uncontrolled n=728
Multicenter observational treatment report
Avedisova et al., Zhurnal Nevrologii i Psikhiatrii, 2011
Among 728 analyzed patients, the report gives CGI-S and CGI-I response rates of 76.0% and 90.8%, adverse events in 3.0%, discontinuation in 0.8%, and no serious adverse events during 28 days.
- Participants / model
- 728 analyzed patients with asthenic disorders and psychoautonomic syndrome across 28 Russian centers
- Treatment
- Oral Ladasten 50 to 100 mg daily
- Follow-up
- 28 days, with a reported one-month follow-up
- Study design
- Russian multicenter report; no controlled allocation stated in the indexed abstract
The abstract describes no controlled allocation.
Read the original source2000 Russian healthy-volunteer study · n=10 acute
Small acute placebo comparison
Viatleva et al., Voenno-Meditsinskii Zhurnal, 2000
In 10 healthy untired men after one oral dose, the abstract reports no change in subjective state or principal operator-performance components, with EEG vigilance and tremor differences interpreted as favorable.
- Participants / model
- 10 healthy, untired male volunteers
- Treatment
- Single oral bromantane exposure versus placebo
- Follow-up
- Acute laboratory assessment
- Study design
- Russian-language comparative report with an English abstract
The English abstract omits the dose. The study did not measure durable cognitive or functional benefit.
Read the original sourceRat mechanism study · dopamine-synthesis enzymes
Preclinical mechanism study
Vakhitova et al., Eksperimentalnaia i Klinicheskaia Farmakologiia, 2004
After 50 mg/kg Ladasten in rats, changes in tyrosine hydroxylase and DOPA decarboxylase expression correlated with L-DOPA and dopamine accumulation in striatum and hypothalamus.
- Participants / model
- Laboratory rats
- Treatment
- Ladasten 50 mg/kg
- Follow-up
- Time-course over the first hours after exposure
- Study design
- Russian preclinical gene-expression and neurochemistry experiment with an English abstract
- Funding
- Non-U.S. government research support indexed by PubMed
No human experiment in this source tested the mechanism, effect size, or dose relationship.
Read the original sourceWADA 2026 · Bromantan prohibited in competition
Official anti-doping standard
World Anti-Doping Agency, effective January 1, 2026
Bromantan appears in S6.A among non-specified stimulants prohibited in competition.
- Participants / model
- Athletes subject to the World Anti-Doping Code
- Treatment
- Bromantan exposure
- Follow-up
- 2026 Prohibited List
- Study design
- Official regulatory standard
Therapeutic-use exemption rules are separate and depend on the applicable anti-doping process.
Read the original sourceWhy is Bromantane in B tier?
B tier comes from Ladasten's marketed-drug history and several human reports in symptomatic patients. The evidence does not show cognitive enhancement in healthy people, establish long-term safety, or authenticate online powder.